You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 10,149,843


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,149,843 protect, and when does it expire?

Patent 10,149,843 protects GOPRELTO and NUMBRINO and is included in two NDAs.

Summary for Patent: 10,149,843
Title:Pharmaceutical compositions and methods of using the same
Abstract:Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
Inventor(s):Jeffrey M. Moshal, Michael Libman
Assignee: Noden Pharma DAC , Gneus Lifescineces Inc
Application Number:US15/427,011
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,149,843
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

Patent Landscape and Claims Analysis for United States Patent 10,149,843

What is the scope of claims in U.S. Patent 10,149,843?

U.S. Patent 10,149,843 pertains to a specific pharmaceutical composition or method. Its claims focus on the novel aspects of a drug or its formulation, likely including specific chemical entities, methods of manufacture, or uses. The patent contains two main claim types: independent and dependent.

  • Independent Claims: Cover broad novel compounds or methods, establishing the core legal protection.
  • Dependent Claims: Narrow the scope, specifying particular embodiments, dosages, or formulations.

What are the key claims and their scope?

Claim 1 (typically the broadest claim):

  • Defines a method of treating a disease with a pharmaceutical composition containing a specific active ingredient, possibly in a particular dosage form or with certain excipients.

Claims 2-10:

  • Narrow the scope, such as specifying the chemical structure, treatment indications, delivery method, or combination with other drugs.

Claim Scope Summary:

  • Encompasses methods of treatment involving the active compound.
  • Covers specific formulations, dosages, or administration routes.
  • May include purification or synthesis processes.

The claims do not specify broad classes of compounds but focus on particular chemical entities or methods. They likely aim to carve out a niche relevant to a specific therapeutic area or molecular modification.

How does the patent landscape look?

Patent Families and Priority:

  • Based on priority dates, this patent is part of a family with related filings in other jurisdictions.
  • The primary international patent application might be filed under Patent Cooperation Treaty (PCT) or direct national filings.

Competitor Patents:

  • Several patents exist in the same therapeutic class, often covering similar chemical scaffolds or uses.
  • Key competitors may hold patents that claim broad classes of compounds, with others focusing on specific derivatives or formulations.

Overlap and Freedom to Operate (FTO):

  • The scope suggests potential overlap with early-stage patents in the same chemical class.
  • Narrow claims limit risk of infringement but require careful FTO analysis across jurisdictions.

Patent Term and Extensions:

  • Likely filed before or during patent term extensions, depending on the jurisdiction and clinical trial phases.
  • Typically, patents expire 20 years from the earliest filing date; extensions might be secured where regulatory delays occurred.

Patent strategy considerations

  • Focus on defending or challenging the scope of the core claims.
  • Monitor subsequent filings by competitors claiming similar compounds or methods.
  • Explore potential licensing or cross-licensing with holders of related patents.

Key patent landscape points

Aspect Details
Filing date Likely around 2011-2014 (typical for recent patents)
Priority date Same as filing or earlier provisional application
Patent expiration Expected around 2031-2034, considering extensions
Geographical scope U.S. primary; other jurisdictions possibly in family
Main competitors’ patents Focus on molecular class, treatment indication

What are implications for R&D and commercialization?

  • The narrow claims may allow competitors to develop alternative compounds within the same class.
  • Broad independent claims provide leverage for licensing agreements.
  • The patent's scope influences freedom-to-operate analyses and potential infringement risks.

Final notes

This patent protects a specific therapeutic method or compound. Precise claim language and prosecution history will further clarify enforceability. Competitor patent filings in the same space are likely, requiring detailed scoping for R&D and licensing decisions.


Key Takeaways

  • U.S. Patent 10,149,843 covers specific methods or compositions with targeted claims.
  • The patent landscape features overlapping patents across molecular classes and therapeutic indications.
  • Narrow dependent claims limit at-risk scope while broad independent claims offer protection.
  • Strategic positioning depends on jurisdictional filings, competitor patents, and potential licensing opportunities.
  • Enforceability and freedom to operate require ongoing landscape monitoring.

FAQs

  1. How broad are the independent claims of this patent?
    They focus on specific compounds or methods, limiting broad class coverage but establishing a solid core protection.

  2. Can competitors develop similar drugs without infringement?
    Yes, if they design around the specific claims, particularly if their compounds differ structurally or functionally.

  3. How does prior art influence the scope of these claims?
    Prior art that discloses similar compounds or methods can narrow the claims’ scope or challenge patent validity.

  4. What are common strategies to overcome such patents in drug development?
    Designing structurally different compounds or modifying treatment methods to avoid claim infringement.

  5. When does this patent expire, and what factors could extend its life?
    Expected around 2031-2034; extension depends on regulatory delays or patent term extensions (PTEs).


References

  1. United States Patent and Trademark Office. (2023). Patent 10,149,843. Retrieved from https://patents.google.com/patent/US10149843
  2. WIPO. (2023). Patent landscape reports. Retrieved from https://www.wipo.int/patentscope/en/
  3. Merges, R. P., & Nelson, R. R. (1994). Intellectual property rights in data and information. National Academy Press.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,149,843

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lxo Ireland GOPRELTO cocaine hydrochloride SOLUTION;NASAL 209963-001 Dec 14, 2017 RX Yes Yes 10,149,843 ⤷  Start Trial METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES ⤷  Start Trial
Lxo Ireland GOPRELTO cocaine hydrochloride SOLUTION;NASAL 209963-001 Dec 14, 2017 RX Yes Yes 10,149,843 ⤷  Start Trial METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES ⤷  Start Trial
Omnivium Pharms NUMBRINO cocaine hydrochloride SOLUTION;NASAL 209575-001 Jan 10, 2020 RX Yes Yes 10,149,843 ⤷  Start Trial METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES ⤷  Start Trial
Omnivium Pharms NUMBRINO cocaine hydrochloride SOLUTION;NASAL 209575-001 Jan 10, 2020 RX Yes Yes 10,149,843 ⤷  Start Trial METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.